Duragen® Secure Post Marketing Clinical Follow-up (PMCF)
- Conditions
- SurgeryDura Mater Nick Cut or Tear
- Registration Number
- NCT02225080
- Lead Sponsor
- Integra LifeSciences Corporation
- Brief Summary
The purpose of this study is to gather information about post-market performance of DuraGen Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market clinical data to evaluate the presence of unintended residual risks associated with the use of DuraGen Secure that were not anticipated or identified in the animal studies, bench studies or clinical evaluation report.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Patient who have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
- Patient who does not agree to allow collection of his/her medical data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient's Outcome Day 30 Patient outcome from the procedure (recovered without sequelae, ongoing with medical intervention, ongoing with surgical intervention, deceased, other)
- Secondary Outcome Measures
Name Time Method Occurence of Adverse Event Between days 15-30 Adverse event that occured between days 15-30 post-operatively
Trial Locations
- Locations (5)
Hopital Lariboisière
🇫🇷Paris, France
die Charité - Universitätsmedizin Berlin
🇩🇪Berlin, Germany
National Hospital for Neurology and Neurosurgery
🇬🇧London, United Kingdom
Hospital Universitario La Fe
🇪🇸Valencia, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain